Advertisement

American Journal of Clinical Dermatology

, Volume 20, Issue 6, pp 829–845 | Cite as

Managing Psoriasis in Patients with HBV or HCV Infection: Practical Considerations

  • Stefano PiasericoEmail author
  • Francesco Messina
  • Francesco Paolo Russo
Review Article

Abstract

Considered more efficacious and safer than traditional systemic drugs, biologic therapies have dramatically improved the quality of life of patients with psoriasis. Recently, there has been a proliferation of new targeted treatment options, including anti-interleukin-17, anti-interleukin-12/23, as well as small-molecule drugs such as apremilast. There are nevertheless some concerns regarding their use, especially in patients with chronic infections such as hepatitis B virus (HBV) and hepatitis C virus (HCV). It has been estimated that two billion individuals are infected with HBV worldwide and approximately 240 million have chronic HBV infection. Moreover, there are approximately 71 million individuals with chronic HCV infection worldwide, with a high percentage of them unaware of being infected. As patients with HBV and HCV infections are excluded from controlled clinical trials investigating new drugs, data regarding their safety in patients with psoriasis are based almost exclusively on case reports and small retrospective cohort studies and need to be constantly updated. The risk of HBV reactivation can be defined as: high risk (≥ 10%), moderate risk (1–10%), and low risk (< 1%) depending on the type of immunosuppressive therapy stratified by the presence or absence of hepatitis B surface antigen but positivity to anti-hepatitis B core antigen. Hepatitis B surface antigen-positive patients treated with tumor necrosis factor-α inhibitors, ustekinumab, or cyclosporine carry a high or moderate risk of HBV reactivation and should be considered candidates for prophylactic anti-HBV therapy. Once therapy is commenced, it is important to check HBV DNA levels every 3 months. Hepatitis B virus reactivation typically occurs with immune reconstitution and therefore antiviral therapy should continue for 6–12 months after stopping immunosuppression. Hepatitis B surface antigen-positive patients who are prescribed methotrexate, acitretin, or apremilast have a low risk and need to be monitored for viral reactivation by determining alanine aminotransferase and HBV DNA levels every 3 months. No conclusive data are available for interleukin-17 and interleukin-23 inhibitors. Anti-hepatitis B core antigen-positive patients treated with tumor necrosis factor-α inhibitors, ustekinumab, and cyclosporine are linked to a moderate risk of reactivation, and they should preferably undergo HBV DNA or hepatitis B surface antigen and alanine aminotransferase testing rather than be subjected to routine pre-emptive therapy. Anti-hepatitis B core antigen-positive patients receiving methotrexate, acitretin, or apremilast have a low risk of reactivation and do not require anti-HBV therapy, nor should monitoring be considered mandatory. No conclusive data are available for interleukin-17 and interleukin-23 inhibitors.

Notes

Compliance with Ethical Standards

Funding

No sources of funding were received for the preparation of this article.

Conflict of interest

Stefano Piaserico has consulted (includes advisory boards, editorial advice, podium presentations, and travel grants) for AbbVie, Almirall, Celgene, Janssen-Cilag, Lilly, MSD, Novartis, and Pfizer. Francesco Messina and Francesco Paolo Russo have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Global hepatitis report 2017. Geneva: World Health Organization; 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.
  2. 2.
    Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Terrault NA, Bzowej NH, Chang K-M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Visram A, Feld JJ. Defining and grading HBV reactivation. Clin Liver Dis. 2015;5:35–8.CrossRefGoogle Scholar
  7. 7.
    Loomba R, Liang TJ, Branch D, et al. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. Gastroenterology. 2017;152:1297–309.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Perrillo RP, Gish R, Ytter YTF, et al. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–44.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Pawlotsky JM, Negro F, Aghemo A et al. European Association for the Study of the Liver (EASL) recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.CrossRefGoogle Scholar
  10. 10.
    Bojito-Marrero L, Pyrsopoulos N. Hepatitis B and hepatitis C reactivation in the biologic era. J Clin Transl Hepatol. 2014;2:240–6.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Bath RK, Brar NK, Forouhar FA, et al. A review of methotrexate-associated hepatotoxicity. J Dig Dis. 2014;15:517–24.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Kujawska A, Clements M, Wise CM, et al. Hepatitis C and methotrexate. Arthritis Rheum. 2003;49:843–5.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Tang KT, Chen YM, Chang SN, et al. Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. J Am Acad Dermatol. 2018;79:652–8.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Van der Veen MJ, Van der Heide A, Kruize AA, et al. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994;53:224–8.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Notarnicola A, Iannone F, Lopalco G, et al. A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy. Reumatismo. 2014;65:298–301.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21:621–7.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Laohapand C, Arromdee E, Tanwandee T. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients. Hepatol Int. 2015;9:202–8.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Fukuda W, Hanyu T, Katayama M, et al. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis. 2017;76:1051–6.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Fujita M, Sugiyama M, Sato Y, et al. Hepatitis B virus reactivation in patients with rheumatoid arthritis: analysis of the National Database of Japan. J Viral Hepat. 2018;25:1312–20.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25:888–9.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Watanabe K, Takase K, Ohno S, et al. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol. 2012;22:470–3.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Tamori A, Koike T, Goto H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–64.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Tan J, Zhou J, Zhao P, et al. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169–75.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Cobeta García JC, Medrano M. Reactivation of hepatitis B in a patient with spondyloarthritis after the suspension of methotrexate and efficacy of treatment with antivirals in association to adalimumab [in Spanish]. Reumatol Clin. 2011;7:200–2.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, et al. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol. 1998;25:2037–8.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hagiyama H, Kubota T, Komano Y, et al. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:375–6.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Chen MH, Chen MH, Liu CY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis. 2017;215:566–73.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Chou C-K, Wang L-H, Lin H-M, et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992;16:13–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Canadian Psoriasis Guidelines Committee. Canadian gidelines for the management of plaque psoriasis. http://www.dermatology.ca/psoriasisguidelines. Accessed Jun 2009.
  30. 30.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Nast A, Gisondi P, Ormerod AD, et al. European S3 guidelines on the systemic treatment of psoriasis vulgaris: update 2015. Short version: EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;2015(29):277–94.Google Scholar
  32. 32.
    Kolios AGA, Yawalkar N, Anliker M, et al. Swiss S1 guidelines on the systemic treatment of psoriasis vulgaris. Dermatology. 2016;232:385–406.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Amatore F, Villani A-P, Tauber M, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33:464–83.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update: short version part 2. Special patient populations and treatment situations. J Dtsch Dermatol Ges. 2018;16:806–13.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Carretero G, Puig L, Dehesa L, et al. Guidelines on the use of methotrexate in psoriasis. Actas Dermosifiliogr. 2010;101:600–13.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Raaby L, Zachariae C, Østensen M, et al. Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a danish expert meeting. Acta Derm Venereol. 2017;97:426–32.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016;175:23–44.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Singh JA, Saag KG, Bridges SLJ, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1–25.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford). 2008;47:924–5.CrossRefGoogle Scholar
  40. 40.
    De Leonardis F, Alivernini S, Bonacci E, et al. Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the ‘3E initiative’ [in Italian]. Reumatismo. 2010;62:34–45.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Flowers MA, Heathcote J, Wanless IR, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med. 1990;112:381–2.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Ito S, Nakazono K, Murasawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum. 2001;44:339–42.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Carrascosa JM, De La Cueva P, Ara M, et al. Metotrexato en psoriasis moderada-grave: revisión de la literatura y recomendaciones de experto. Actas Dermosifiliogr. 2016;107:194–206.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Noguchi O, Gibo Y. Induction of clinical remission with adalimumab-methotrexate combination therapy in a patient with rheumatoid arthritis and concomitant hepatitis C virus infection. Mod Rheumatol. 2011;21:696–700.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Nissen MJ, Fontanges E, Allam Y, et al. Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon. Rheumatology. 2005;44:1016–20.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Mok MY, Ng WL, Yuen MF, et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol. 2000;18:363–8.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Iannone F, La Montagna G, Bagnato G, et al. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol. 2014;41:286–92.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Pilkington T, Brogden RN. Acitretin: a review of its pharmacology and therapeutic use. Drugs. 1992;43:597–627.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;61:1044–55.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Erkek E, Karaduman A, Akcan Y, et al. Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis. Dermatology. 2000;201:179–81.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Behnam SE, Hindiyeh R, Fife DJ, et al. Etanercept as prophylactic psoriatic therapy before interferon-alpha and ribavirin treatment for active hepatitis C infection. Clin Exp Dermatol. 2010;35:397–8.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Kruger-Krasagakes S, Grabbe J, Czarnetzki BM. Possible aggravation of hepatitis A by acitretin. Acta Derm Venereol. 1995;75:82–3.PubMedPubMedCentralGoogle Scholar
  53. 53.
    Carretero G, Ribera M, Belinchón I, et al. Guidelines for the use of acitretin in psoriasis. Actas Dermosifiliogr. 2013;104:598–616.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Sauder MB, Cheung L, Beecker J. Acitretin-induced hepatitis: when to monitor cholestatic enzymes. J Cutan Med Surg. 2015;19:115–20.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Roenigk HH Jr, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol. 1999;41:584–8.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Ormerod AD, Campalani E, Goodfleld MJD. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol. 2010;162:952–63.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Urata Y, Uesato R, Tanaka D, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21:16–23.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Xia W, Xie H, Shen Y, et al. Effects of ciclosporin and tacrolimus on replication of hepatitis B virus in vitro: a comparative study [in Chinese]. Zhonghua Yi Xue Za Zhi. 2006;86:111–5.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Tian X, Zhao C, Zhu H, et al. Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin A secretion: possible link to pathogenesis of HBV infection. J Virol. 2010;84:3373–81.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Xia WL, Shen Y, Zheng S. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms. Hepatobiliary Pancreat Dis Int. 2005;4:18–22.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis. 2006;65:983–9.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Ishii N, Watashi K, Hishiki T, et al. Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol. 2006;80:4510–20.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Nakagawa M, Sakamoto N, Enomoto N, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004;313:42–7.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Galeazzi M, Bellisai F, Giannitti C, et al. Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci. 2007;1110:544–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22:6444–55.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Kamar N, Selves J, Sandres-Saune K, et al. Does cyclosporine have a beneficial effect on the course of chronic hepatitis C infection after renal transplantation? Transpl Proc. 2006;38:1329–32.CrossRefGoogle Scholar
  67. 67.
    Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19:23–32.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Fotiadou C, Trakatelli M, Papathemeli DLE. Safety of apremilast in the treatment of a psoriasis patient with chronic hepatitis B. Progr Abstr. 5th World Psoriasis & Psoriatic Arthritis Conference; 27–30 June 2018; Stockholm.Google Scholar
  69. 69.
    Reddy SP, Shah VV, Wu JJ. Apremilast for a psoriasis patient with HIV and hepatitis C. J Eur Acad Dermatol Venereol. 2017;481:481–2.CrossRefGoogle Scholar
  70. 70.
    Jeon C, Nakamura M, Sekhon S, et al. Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Rep. 2017;3:495–7.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    European Medicines Agency (EMA). Otezla product information. http://ec.europa.eu/health/documents/community-register/2018/20180802142022/anx_142022_en.pdf. Accessed 11 May 2019.
  72. 72.
    Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr Med Chem. 2017;24:3054–67.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Gobejishvili L, Barve S, Breitkopf-Heinlein K, et al. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4. J Pharmacol Exp Ther. 2013;347:80–90.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Lopetuso RL, Mocci G, Marzo M, et al. Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver. Int J Mol Sci. 2018.  https://doi.org/10.3390/ijms19082199.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31:774–90.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    French JB, Bonacini M, Ghabril M, et al. Hepatotoxicity associated with the use of anti-TNF-alpha agents. Drug Saf. 2016;39:199–208.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31.e1–15.CrossRefGoogle Scholar
  78. 78.
    Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612–7.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Björnsson ES, Gunnarsson BI, Gröndal G, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13:602–8.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Maini MK, Boni C, Lee CK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269–80.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Jeng J-E, Tsai J-F, Chuang L-Y, et al. Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia. 2007;9:987–92.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–7.CrossRefGoogle Scholar
  83. 83.
    Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–72.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–68.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    EASL. clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370–98.Google Scholar
  86. 86.
    Ballanti E, Conigliaro P, Chimenti MS, et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014;75(Suppl. 1):S42–5.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Nakamura J, Nagashima T, Nagatani K, et al. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis. 2016;19:470–5.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Navarro R, Concha-Garzon MJ, Castano C, et al. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol. 2014;53:909–11.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Sanz-Bueno J, Vanaclocha F, García-Doval I, et al. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the BIOBADADERM database. Actas Dermosifiliogr. 2015;106:477–82.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Giardina AR, Ferraro D, Ciccia F, et al. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study. Clin Exp Rheumatol. 2013;31:25–30.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Nosotti L, Francesconi F, Izzi S, et al. Safety of antitumour necrosis factor-alpha therapy in psoriatic patients with hepatitis B virus infection. Br J Dermatol. 2010;162:1408–10.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Prignano F, Ricceri F, Pescitelli L, et al. Tumour necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol. 2011;164:645–7.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Clarke WT, Amin SS, Papamichael K, et al. Patients with core antibody positive and surface antigen negative hepatitis B (anti-HBc+, HBsAg−) on anti-TNF therapy have a low rate of reactivation. Clin Immunol. 2018;191:59–62.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Giannitti C, Lopalco G, Vitale A, et al. Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study. Clin Exp Rheumatol. 2017;35:93–7.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Pauly MP, Tucker L-Y, Szpakowski J-L, et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2018;16(1964–73):e1.Google Scholar
  96. 96.
    Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77:88–97.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11:R179.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken). 2010;62:749–54.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Lan J-L, Chen Y-M, Hsieh T-Y, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011;70:1719–25.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Papa A, Felice C, Marzo M, et al. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohns Colitis. 2013;7:113–9.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Laurenti R, Giovannangeli F, Gubinelli E, et al. Long-term safety of anti-TNF adalimumab in HBc antibody-positive psoriatic arthritis patients: a retrospective case series of 8 patients. Clin Dev Immunol. 2013;2013:410521.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Ye H, Zhang X, Mu R, et al. Anti-TNF therapy in patients with HBV infection: analysis of 87 patients with inflammatory arthritis. Clin Rheumatol. 2014;33:119–23.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Mori S. Do low titers of antibody against hepatitis B surface antigen carry a risk of viral reactivation during immunosuppressive therapy for rheumatic diseases? J Rheumatol. 2012;39:1292–3 (author reply 1293).PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Kato M, Atsumi T, Kurita T, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases. J Rheumatol. 2011;38:2209–14.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Morisco F, Guarino M, La Bella S, et al. Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis. BMC Gastroenterol. 2013;20:200–8.Google Scholar
  106. 106.
    Piaserico S, Dapavo P, Conti A, et al. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017;31:1853–9.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    AlMutairi N, Abouzaid HA. Safety of biologic agents for psoriasis in patients with viral hepatitis. J Dermatolog Treat. 2018;29:553–6.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Morisco F, Castiglione F, Rispo A, et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis. 2011;43(Suppl. 1):S40–8.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Biondo MI, Germano V, Pietrosanti M, et al. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med. 2014;25:482–4.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Cassano N, Mastrandrea V, Principi M, et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents. 2011;25:285–9.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010;69:1352–5.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40–6.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Cantini F, Boccia S, Goletti D, et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-alpha) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol. 2014;2014:926836.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol. 2015;21:10274–89.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–71.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Kim YJ, Bae S-C, Sung Y-K, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37:346–50.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11:558–64.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol. 2013;23:694–704.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    De Nard F, Todoerti M, Grosso V, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: extending perspective from old to newer drugs. World J Hepatol. 2015;7:344–61.CrossRefGoogle Scholar
  120. 120.
    Paul S, Dickstein A, Saxena A, et al. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology. 2017;66:379–88.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Jeon JW, Kim SM, Cho H, et al. Presence of hepatitis B surface antibody in addition to hepatitis B core antibody confers protection against hepatitis B virus infection in hepatitis B surface antigen-negative patients undergoing kidney transplantation. Transplantation. 2018;102:1717–23.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Oketani M, Ido A, Uto H, et al. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627–36.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum. 2008;38:208–17.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: an update on current recommendations. World J Hepatol. 2016;8:385–94.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Koutsianas C, Thomas K, Vassilopoulos D. Hepatitis B reactivation in rheumatic diseases: screening and prevention. Rheum Dis Clin North Am. 2017;43:133–49.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Gonzalez SA, Perrillo RP. Hepatitis B virus reactivation in the setting of cancer chemotherapy and other immunosuppressive drug therapy. Clin Infect Dis. 2016;62(Suppl. 4):S306–13.PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Rahier J-F, Moutschen M, Van Gompel A, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49:1815–27.CrossRefGoogle Scholar
  130. 130.
    Rysgaard CD, Morris CS, Drees D, et al. Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem. BMC Clin Pathol. 2012;12:15.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Pompili M, Biolato M, Miele L, et al. Tumor necrosis factor-alpha inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19:7867–73.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Ray RB, Meyer K, Steele R, et al. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem. 1998;273:2256–9.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Kallinowski B, Haseroth K, Marinos G, et al. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol. 1998;111:269–77.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Kishihara Y, Hayashi J, Yoshimura E, et al. IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci. 1996;41:315–21.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487–94.PubMedCrossRefPubMedCentralGoogle Scholar
  136. 136.
    Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315–22.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078–82.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006;45:1294–7.CrossRefGoogle Scholar
  139. 139.
    Di Nuzzo S, Boccaletti V, Fantini C, et al. Are anti-TNF-alpha agents safe for treating psoriasis in hepatitis C virus patients with advanced liver disease? Case reports and review of the literature. Dermatology. 2016;232:102–6.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Pescitelli L, Lazzeri L, Tripo L, et al. Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis. Dermatol Ther. 2018;31:e12614.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Damiani G, Franchi C, Pigatto P, et al. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new direct-acting antiviral agents. World J Hepatol. 2018;10:329–36.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Imperatore N, Castiglione F, Rispo A, et al. Timing strategies of direct-acting antivirals and biologics administration in HCV-infected subjects with inflammatory bowel diseases. Front Pharmacol. 2017;8:867.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66:153–94.CrossRefGoogle Scholar
  144. 144.
    Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008;67(Suppl. 3):iii2–25.PubMedPubMedCentralGoogle Scholar
  145. 145.
    Ding T, Ledingham J, Luqmani R, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford). 2010;49:2217–9.CrossRefGoogle Scholar
  146. 146.
    Koskinas J, Tampaki M, Doumba PP, et al. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface-antigen-negative anti-HBs-positive patient. Br J Dermatol. 2013;168:679–80.PubMedCrossRefPubMedCentralGoogle Scholar
  147. 147.
    Paquissi FC. Immunity and fibrogenesis: the role of Th17/IL-17 axis in HBV and HCV-induced chronic hepatitis and progression to cirrhosis. Front Immunol. 2017;8:1–16.CrossRefGoogle Scholar
  148. 148.
    Ting S-W, Chen Y-C, Huang Y-H. Risk of hepatitis B reactivation in patients with psoriasis on ustekinumab. Clin Drug Investig. 2018;38:873–80.PubMedCrossRefPubMedCentralGoogle Scholar
  149. 149.
    Steglich RB, Cheinquer H, Meneghello LP, et al. The use of ustekinumab in a patient with severe psoriasis and positive HBV serology. An Bras Dermatol. 2014;89:652–4.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Piaserico S, Conti A, Coati I, et al. Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. G Ital Dermatol Venereol. 2019;154(3):376–7.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168:609–16.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41:974–80.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Llamas-Velasco M, Concha-Garzón MJ, García-Diez A, et al. Liver injury in psoriasis patients receiving ustekinumab: a retrospective study of 44 patients treated in the clinical practice setting. Actas Dermosifiliogr. 2015;106:470–6.PubMedCrossRefPubMedCentralGoogle Scholar
  154. 154.
    Chiu H-Y, Chen C-H, Wu M-S, et al. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol. 2013;169:1295–303.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Raymundo A, Facin AB, de Castro CS, et al. Safety of ustekinumab in severe psoriasis with chronic hepatitis B. Indian J Dermatol Venereol Leprol. 2016;82:326–89.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Opel D, Economidi A, Chan D, et al. Two cases of hepatitis B in patients with moderate to severe psoriasis with ustekinumab. J Drugs Dermatol. 2012;11:1498–501.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Abuchar A, Vitiello M, Kerdel FA. Psoriasis treated with ustekinumab in a patient with hepatitis C. Int J Dermatol. 2013;52:381–2.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Kikuchi S, Umezawa Y, Chihara M, et al. Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment. J Dermatol. 2018;45:e59–60.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Meng F, Wang K, Aoyama T, et al. IL-17 signaling in inflammatory cells, Kupffer cells and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology. 2012;143:1–18.CrossRefGoogle Scholar
  160. 160.
    Siegel SAR, Winthrop KL, Ehst BD, et al. 191 Secukinumab treatment of individuals with psoriasis infected with hepatitis B and/or hepatitis C virus. J Invest Dermatol. 2017;137:S32.CrossRefGoogle Scholar
  161. 161.
    Chiu H, Hui R, Huang Y, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98:829–34.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    Peccerillo F, Odorici G, Pellacani G, et al. Secukinumab: a positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. Dermatol Ther. 2018;31:e12601.PubMedCrossRefGoogle Scholar
  163. 163.
    Bevans SL, Mayo TT, Elewski BE. Safety of secukinumab in hepatitis B virus. J Eur Acad Dermatol Venereol. 2018;32:e120–1.PubMedCrossRefGoogle Scholar
  164. 164.
    Yanagihara S, Sugita K, Yoshida Y, et al. Psoriasis vulgaris in a hepatitis B virus carrier successfully treated with secukinumab and entecavir combination therapy. Eur J Dermatol. 2017;27:185–6.PubMedPubMedCentralGoogle Scholar
  165. 165.
    Chu CH, Davis C. Urticarial reaction to ustekinumab during the treatment of plaque psoriasis in a hepatitis C-positive patient. Drug Saf Case Rep. 2017;4:9.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Lora V, Graceffa D, De Felice C, et al. Treatment of severe psoriasis with ixekizumab in a liver transplant recipient with concomitant hepatitis B virus infection. Dermatol Ther. 2019.  https://doi.org/10.1111/dth.12909.CrossRefPubMedPubMedCentralGoogle Scholar
  167. 167.
    Koike Y, Fujiki Y, Higuchi M, et al. An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. JAAD Case Rep. 2019;5:150–2.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Dermatology Unit, Department of MedicineUniversity of PadovaPaduaItaly
  2. 2.Gastroenterology Unit, Department of Surgical, Oncological and Gastroenterological SciencesUniversity of PaduaPaduaItaly

Personalised recommendations